<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233805</url>
  </required_header>
  <id_info>
    <org_study_id>EC00-01</org_study_id>
    <nct_id>NCT00233805</nct_id>
  </id_info>
  <brief_title>The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.</brief_title>
  <acronym>RAVEL</acronym>
  <official_title>A Randomized Study With the Sirolimus Coated Modified BX Velocity Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the sirolimus
      coated Bx VELOCITY stent in reducing angiographic in-stent late loss in de novo native
      coronary lesions as compared to the bare metal Bx VELOCITY balloon-expandable stent. Both
      stents will be mounted on the Raptor Rapid Exchange Delivery Stent System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter (19 sites), prospective, randomized study. This study has a 2 arm
      design assessing the safety and effectiveness of the sirolimus coated BxTM VELOCITY stent to
      the bare metal BxTM VELOCITY stent, both mounted on the Raptorâ Rapid Exchange Stent Delivery
      System. A total of 220 patients will be entered in the study and will be randomized on a 1:1
      basis. Patients will be randomized to the coated or uncoated BX VELOCITY stent. Therefore,
      neither the Investigator nor the patient will know which stent will be implanted. Patients
      will be followed for twelve months post-procedure, with all patients having a repeat
      angiography at 6 months. An ancillary study with in-stent IVUS measurements at 6 months
      follow-up will be performed in all patients of 6 pre-selected clinical sites. It is assumed
      that these sites will enroll more than 90 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic in-stent late loss as determined by Quantitative Coronary Angiography.</measure>
    <time_frame>6 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-stent mean %DS by QCA</measure>
    <time_frame>post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-target vessel segment MLD</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent MLD</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>6 and 12 months; or 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization</measure>
    <time_frame>6 and 12 months; or 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>30 days; 6 and 12 months; or 2, 3, 4 and 5 years;</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neo-intimal growth assessed by IVUS</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus coated Bx Velocity™</intervention_name>
    <description>drug-eluting stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare metal Bx Velocity™</intervention_name>
    <description>bare-metal stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald
             Classification B&amp;C, I-II-III) OR patients with documented silent ischemia;

          2. Single treatment of de novo lesion in a coronary artery which can be appropriately
             covered by a study stent of 18mm in length in patients with single or multivessel
             disease; patients with multiple lesions can be included only if the other lesions do
             not require treatment;

          3. Target lesion is &gt;= 2.5 and &lt;= 3.5mm in diameter (visual estimate);

          4. Target lesion is located in a native coronary artery which can be covered by one stent
             (single lesion);

          5. Target lesion stenosis is &gt;50% and &lt;100% (TIMI I) (visual estimate).

        Exclusion Criteria:

          1. A Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the
             CK and CK-MB enzymes are back to normal;

          2. Unprotected left main coronary disease with &gt;=50% stenosis;

          3. Have an ostial target lesion;

          4. Angiographic evidence of thrombus within target lesion;

          5. Calcified lesions which cannot be successfully predilated;

          6. Ejection fraction &lt;=30%;

          7. Totally occluded vessel (TIMI 0 level);

          8. Target lesion involves bifurcation including a side branch &gt;=2.5mm in diameter (either
             stenosis of both main vessel and major branch or stenosis of just major branch) that
             would require side branch stenting which is likely to occur if side branch is diseased
             and intended to be stented;

          9. Planned Direct Stenting.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Claude Morice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Hospitalier Jacques Cartier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Marie-Claude Morice</name>
      <address>
        <city>Massy</city>
        <zip>F- 91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hoffmann R, Morice MC, Moses JW, Fitzgerald PJ, Mauri L, Breithardt G, Schofer J, Serruys PW, Stoll HP, Leon MB. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart. 2008 Mar;94(3):322-8. Epub 2007 Aug 29.</citation>
    <PMID>17761505</PMID>
  </reference>
  <results_reference>
    <citation>Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E, Wülfert E. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005 Mar 1;111(8):1040-4. Epub 2005 Feb 21.</citation>
    <PMID>15723977</PMID>
  </results_reference>
  <results_reference>
    <citation>Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, Wietze L, Sousa JE, Serruys PW, Morice MC; Ravel Investigators. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J. 2004 Jan;25(2):107-12.</citation>
    <PMID>14720526</PMID>
  </results_reference>
  <results_reference>
    <citation>Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W, Bartorelli A, Constantini C, Degertekin M, Tanabe K, Disco C, Wuelfert E, Morice MC; RAVEL Study Group. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002 Oct 8;106(15):1949-56.</citation>
    <PMID>12370218</PMID>
  </results_reference>
  <results_reference>
    <citation>Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC; RAVEL Study Group. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002 Aug 13;106(7):798-803.</citation>
    <PMID>12176950</PMID>
  </results_reference>
  <results_reference>
    <citation>Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007 Oct 2;50(14):1299-304. Epub 2007 Sep 17.</citation>
    <PMID>17903626</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>August 5, 2008</last_update_submitted>
  <last_update_submitted_qc>August 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll - Director Clinical Affairs</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

